Is NCT06859424 recruiting in Boston, MA?

Yes, NCT06859424 is currently recruiting participants at its Boston, MA location. This blood cancer clinical trial is actively enrolling qualified participants.

How do I join the blood cancer clinical trial in Boston?

To join this clinical trial in Boston, complete the eligibility form on this page. A study coordinator will contact you to discuss next steps and determine if you qualify.

Is participation in this Boston clinical trial free?

Yes, all study-related care is provided at no cost to qualified participants. Many studies also offer compensation for time and travel expenses.

Blood Cancer Clinical Trial in Boston, MA

About This Blood Cancer Study in Boston

The purpose of this clinical trial is to compare drug combinations to learn which drugs work best to prevent graft-versus-host-disease (GVHD) in people who have received a stem cell transplant. The source of stem cells is from someone who is not related and has a different blood cell type than the study participant. The researchers will compare the new drug combination to a standard drug combination. They will also learn about the safety of each drug combination. Participants will: * Receive t

Sponsor: Center for International Blood and Marrow Transplant Research

Who Can Participate

Inclusion Criteria

, MAC RECIPIENTS:

Age 18 to \< 66 years (chemotherapy-based conditioning) or \< 61 years (TBI-based conditioning) at the time of signing informed consent

Patient or legally authorized representative has the ability to provide informed consent according to the applicable regulatory and institutional requirements

Stated willingness to comply with all study procedures and availability for the duration of the study

Planned MAC regimen (see Table 8 in Section 7.4 for allowed MAC regimens)

Available partially HLA-MMUD (4/8-7/8 at HLA-A, -B, -C, and -DRB1 is required) with age 16-35

Product planned for infusion is MMUD T-cell replete PBSC as allograft

HCT-CI \< 5 (Appendix H - Hematopoietic Cell Transplant Comorbidity Index Scoring). The presence of prior malignancy will not be used to calculate HCT-CI for this trial, to allow for the inclusion of patients with secondary or therapy-related AML or MDS.

One of the following diagnoses:

AML, ALL, or other acute leukemia in first remission or beyond with ≤ 5% marrow blasts and no circulating blasts or evidence of extramedullary disease. Documentation of bone marrow assessment will be accepted within 45 days prior to the anticipated start of conditioning.

Patients with MDS with no circulating blasts and with \< 10% blasts in the bone marrow (higher blast percentage allowed in MDS due to lack of differences in outcomes with \< 5% vs 5-10% blasts in MDS). Documentation of bone marrow assessment will be accepted within 45 days prior to the anticipated start of conditioning.

Cardiac function: Left ventricular ejection fraction ≥ 45% based on most recent echocardiogram or multi-gated acquisition scan (MUGA) results

Estimated creatinine clearance ≥ 45mL/min calculated by equation

Pulmonary function: diffusing capacity of the lungs for carbon monoxide (DLCO) corrected for hemoglobin ≥ 50% and forced expiratory volume in first second (FEV1) predicted ≥ 50% based on most recent PFT results

Liver function acceptable per local institutional guidelines

KPS of ≥ 70% (Appendix I - Performance Status) Inclusion Criteria, RIC/NMA RECIPIENTS:

Age ≥ 18 years at the time of signing informed consent

Patient or legally authorized representative has the ability to provide informed consent according to the applicable regulatory and local institutional requirements

Stated willingness to comply with all study procedures and availability for the duration of the study

Planned NMA/RIC regimen (see

Table 9 in Section 7.4 for allowed NMA/RIC regimens)

Available partially HLA-MMUD (4/8-7/8 at HLA-A, -B, -C, and -DRB1 is required) with age 16-35

Product planned for infusion is MMUD T-cell replete PBSC allograft

One of the following diagnoses:

Patients with acute leukemia or chronic myeloid leukemia (CML) with no circulating blasts, no evidence of extramedullary disease, and with \< 5% blasts in the bone marrow. Documentation of bone marrow assessment will be accepted within 45 days prior to the anticipated start of conditioning.

Patients with MDS with no circulating blasts and with \< 10% blasts in the bone marrow (higher blast percentage allowed in MDS due to lack of differences in outcomes with \< 5% vs 5-10% blasts in MDS.) Documentation of bone marrow assessment will be accepted within 45 days prior to the anticipated start of conditioning.

Patients with chronic lymphocytic leukemia (CLL) or other leukemias (including prolymphocytic leukemia) with chemosensitive disease at time of transplantation.

Higher-risk chronic myelomonocytic leukemia (CMML) according to CMML-specific prognostic scoring system or high-risk MDS/myeloproliferative neoplasms (MPN) not otherwise specified are eligible, provided there is no evidence of high-grade bone marrow fibrosis or massive splenomegaly at the time of enrollment.

Patients with lymphoma with chemosensitive disease at the time of transplantation.

Patients with primary myelofibrosis or myelofibrosis secondary to essential thrombocythemia, polycythemia vera or MDS with grade 4 fibrosis.

Cardiac function: Left ventricular ejection fraction ≥ 40% based on most recent echocardiogram or MUGA results with no clinical evidence of heart failure

Estimated creatinine clearance ≥ 45mL/min calculated by equation

Pulmonary function: DLCO corrected for hemoglobin ≥ 50% and FEV1 predicted ≥ 50% based on most recent PFT results

Liver function acceptable per local institutional guidelines

KPS of ≥ 60% (Appendix I - Performance Status)

Exclusion Criteria

Suitable HLA-matched related or 8/8 high-resolution matched unrelated donor available

Subject unwilling or unable to give informed consent, or unable to comply with the protocol including required follow-up and testing

Subjects with a prior allogeneic transplant

Subjects with an autologous transplant within the past 3 months

Subjects who are breastfeeding or pregnant

Uncontrolled bacterial, viral or fungal infection at the time of the transplant preparative regimen

Concurrent enrollment on a GVHD prevention clinical trial

Subjects who undergo desensitization to reduce anti-donor HLA antibody levels prior to transplant

Patients who are HIV-positive with persistently positive viral load. HIV-infected patients on effective anti-retroviral therapy (ART) with undetectable viral load within 6 months are eligible for this trial. Patients with well-controlled HIV are eligible provided resistance panels are negative, the patient is compliant with ART, and their disease remains well controlled.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Boston?

Yes, this clinical trial (NCT06859424) has an active research site in Boston, MA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Blood Cancer Treatment Options in Boston, MA

If you're searching for blood cancer treatment options in Boston, MA, this clinical trial (NCT06859424) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Boston research site is actively enrolling participants for this phase 2 clinical trial. You'll receive care from experienced blood cancer specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all blood cancer clinical trials near you to find additional studies recruiting in your area.

Blood Cancer Clinical Trial in Boston, MA

Expert Care in Boston

IRB Approved

No-Cost Care

Apply for This Boston Location

Why Participate?

Simple Process